Details for New Drug Application (NDA): 207961
✉ Email this page to a colleague
The generic ingredient in DABIGATRAN ETEXILATE MESYLATE is dabigatran etexilate mesylate. There is one drug master file entry for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the dabigatran etexilate mesylate profile page.
Summary for 207961
| Tradename: | DABIGATRAN ETEXILATE MESYLATE |
| Applicant: | Hetero Labs Ltd Iii |
| Ingredient: | dabigatran etexilate mesylate |
| Patents: | 0 |
Pharmacology for NDA: 207961
| Mechanism of Action | Thrombin Inhibitors |
Medical Subject Heading (MeSH) Categories for 207961
Suppliers and Packaging for NDA: 207961
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DABIGATRAN ETEXILATE MESYLATE | dabigatran etexilate mesylate | CAPSULE;ORAL | 207961 | ANDA | Camber Pharmaceuticals, Inc. | 31722-621 | 31722-621-32 | 10 BLISTER PACK in 1 CARTON (31722-621-32) / 6 CAPSULE in 1 BLISTER PACK |
| DABIGATRAN ETEXILATE MESYLATE | dabigatran etexilate mesylate | CAPSULE;ORAL | 207961 | ANDA | Camber Pharmaceuticals, Inc. | 31722-621 | 31722-621-60 | 60 CAPSULE in 1 BOTTLE (31722-621-60) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 75MG BASE | ||||
| Approval Date: | May 6, 2020 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 150MG BASE | ||||
| Approval Date: | May 6, 2020 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 110MG BASE | ||||
| Approval Date: | Aug 13, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
